Stem cells for degenerative disc disease
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Degenerative disc disease describes the progressive loss of hydration and height in the intervertebral discs, a common driver of chronic low back and neck pain. Intradiscal mesenchymal stem cell injection is one of the better-studied orthopaedic regenerative applications.
How MSCs are used in disc degeneration
The nucleus pulposus has poor blood supply and limited self-repair capacity. Injecting MSCs into the disc aims to modulate the inflammatory environment, support the remaining nucleus cells and slow further matrix breakdown. Injection is image-guided and performed in a hospital setting.
It is a pain-and-function intervention. Regrowing a collapsed disc is not a realistic objective, and patients with advanced collapse or instability are usually better served by spinal surgical review.
Evidence at a glance — Degenerative disc disease
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — early-stage only
- Randomised trials?
- A small number of randomised and sham-controlled trials with mixed results
- Main outcomes studied
- Back pain (VAS)
- Disability (ODI)
- Disc hydration on MRI
- Long-term evidence
- Very limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Degenerative disc disease — PubMed
- Randomised controlled trials — Degenerative disc disease — PubMed
- Registered MSC trials — Degenerative disc disease — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
Who is a candidate
Imaging and symptom pattern both matter.
- Discogenic pain confirmed on MRI, typically Pfirrmann grade III–IV
- Preserved disc height sufficient for injection
- Pain persisting beyond 6 months despite physiotherapy and conservative care
- No severe canal stenosis, segmental instability or cauda equina signs
- Not already scheduled for fusion — compare in our therapy-versus-surgery guidance
What results look like
Reported outcomes centre on pain score and disability index improvement over 6–12 months, with imaging change less consistent. Structured physiotherapy after the procedure materially affects outcome and is part of the plan, not an optional extra.
Related pathways: joint and orthopaedic therapy, spinal cord injury.
Frequently asked questions
Can stem cells regenerate a spinal disc?
Meaningful regrowth of a severely degenerated disc has not been demonstrated. The realistic target is reduced pain and improved function, with slower progression.
Is the injection painful?
It is performed under local anaesthetic with imaging guidance and mild sedation where appropriate. Post-procedure soreness for a few days is expected.
How soon can I fly home?
Most patients travel 2–3 days after the procedure, following an activity plan for the first weeks.
Ask whether this is right for you
Share your diagnosis and recent records. Our medical team in Istanbul reviews candidacy, alternatives and realistic goals before any treatment plan is proposed.
Request a free medical review